Rankings
▼
Calendar
ANIK Q3 2024 Earnings — Anika Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ANIK
Anika Therapeutics, Inc.
$213M
Q3 2024 Earnings
Healthcare
Medical - Devices
Income Statement
Revenue
$39M
-6.5% YoY
Gross Profit
$1M
3.7% margin
Operating Income
-$28M
-72.3% margin
Net Income
-$30M
-77.2% margin
EPS (Diluted)
$-2.03
QoQ Revenue Growth
+26.1%
Cash Flow
Operating Cash Flow
$5M
Free Cash Flow
$3M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$231M
Total Liabilities
$52M
Stockholders' Equity
$180M
Cash & Equivalents
$62M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$39M
$41M
-6.5%
Gross Profit
$1M
$25M
-94.2%
Operating Income
-$28M
-$8M
-265.1%
Net Income
-$30M
-$7M
-355.0%
Revenue Segments
Joint Preservation and Restoration
$12M
83%
Non-Orthopedic
$2M
17%
Geographic Segments
UNITED STATES
$28M
83%
Europe
$6M
17%
← FY 2024
All Quarters
Q4 2024 →